ORIGINAL

Serum YKL-40 Level is Associated with Geriatric Nutritional Risk Index (GNRI) and γ-GTP in Hemodialysis Patients

Kohsuke Yamada1,2, Toru Hyodo2, Syunichiro Urabe2, Satomi Haga2, and Toshio Hosaka3

1Department of Nutrition and Dietetics, Kamakura Women’s University, Kamakura City, Japan, 2Dialysis Center, Eijin Clinic, Hiratsuka City, Japan, 3Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, Shizuoka City, Japan

Abstract: Chitinase-3-like protein 1 (YKL-40) is a glycoprotein associated with inflammation and tissue remodelling that has recently been used as a marker of inflammation in hemodialysis (HD) patients. In this study, we aimed to determine whether YKL-40 has potential to serve as a nutritional parameter in Japanese HD patients. The serum YKL-40 concentration, hematological parameters, inflammatory marker levels, anthropometric measurements, and laboratory values were measured in 88 patients receiving HD. The geriatric nutritional risk index (GNRI) was used as a nutritional assessment tool. 45.4% of patients were malnourished. YKL-40 correlated positively with age, alkaline phosphatase, alanine transaminase and γ-glutamyl transpeptidase (γ-GTP) levels, but not with nutritional status, and correlated inversely with ankle brachial index score, a predictor of atherosclerosis. Furthermore, multiple regression analysis confirmed that γ-GTP, GNRI and age correlated with YKL-40. YKL-40 elevation was associated with γ-GTP, GNRI and age in HD patients. J. Med. Invest. 69: 101-106, February, 2022

Keywords: YKL-40, γ-GTP, hemodialysis, malnutrition, inflammation

INTRODUCTION

Chitinase-3-like protein 1 (YKL-40) derives its name from a structure which consists of three N-terminal amino acids, tyrosine (Y), lysine (K) and leucine (L). The molecular mass of YKL-40 is 40 kDa. YKL-40 is secreted by cancer cells, macrophages and neutrophils, and is known to be involved in cell proliferation and differentiation, as well as angiogenesis and inflammation (1-5). Moreover, serum YKL-40 level increases in association with hepatopathy and fibrosis of hepatocytes (6-16). Elevated YKL-40 is associated with liver fibrosis and also with endothelial damage (14).

Hemodialysis (HD) patients are typically undernourished, and it is widely believed that prolonged malnutrition and chronic inflammation increase the risk of arteriosclerosis. Therefore, evaluation of the associations among malnutrition and inflammation is important for improving the survival of HD patients (17).

Recently, urinary YKL-40 level was reported to increase in response to tubular cell damage in acute kidney injury (18-21). In diabetic patients, plasma and urinary YKL-40 levels are associated with the progression of diabetic nephropathy (22-25). YKL-40 is also reportedly useful as an inflammation marker in HD patients (26-29). However, little is known about the association between YKL-40 and nutritional status in HD patients. Herein, we evaluated the association of YKL-40 with nutritional-related parameters in Japanese HD patients.

MATERIALS AND METHODS

Subjects

The subjects were recruited from among HD patients at Eijin Clinic (Kanagawa, Japan), which is an outpatient facility. The study inclusion criteria were ongoing HD therapy for at least 6 months prior to enrollment and being in stable condition without co-morbidities such as heart failure, infection, cirrhosis, respiratory disease, nephrotic syndrome, malignancy, liver injury, or severe inflammation. None of the patients were perioperative or had suffered recent severe injuries. Because of the high incidence of kidney cancer in HD patients, computed tomography (CT) is routinely performed for screening. Cases suspected to have low-density fatty liver based on CT images suggesting liver injuries and disorders, including hepatitis, were excluded. In total, 88 patients (65 men, 23 women) were enrolled in the study (Figure 1). The mean age, presented as the mean ± standard deviation (SD), was 68.5 ± 13.5 years, and the mean HD duration was 6.2 ± 5.8 years. The prevalence of diabetes among our subjects was 52.3%. The patients had been provided dietary

Assessed for eligibility (n=100)

Excluded: Missing data (n=15)

Not meeting inclusion criteria (n=6)

Final analysis (n=88)

Figure 1. Flow diagram of inclusion and exclusion criteria
YKL-40 is associated with MIA syndrome in HD

K. Yamada, et al.

RESULTS

The basic characteristics of the study participants, some of which are analyzed by gender such as anthropometric factor, are presented in Tables 1 and 2. The serum YKL-40 level of these subjects was 157.9 ± 85.5 ng/mL. This level was more than three times that in for healthy subjects and similar to the value obtained in a prior study of HD patients. (27, 30). Protein intake was 0.83 ± 0.16 g/kg/day. The recommended protein intake is 0.9 to 1.2 g/kg/day according to the guidelines of the Japanese Society for Dialysis Therapy. The patients tended to have lower protein intake overall. In fact, 45.4% of patients were undernourished according to the GNRI. The prevalence of diabetes was 52.3% in patients (Table 3), including two patients diagnosed with diabetes after starting HD therapy. Serum YKL-40 levels did not differ significantly between the diabetic and non-diabetic groups (142.05 ± 83.75 vs 175.59 ± 86.01, p = 0.077). Univariate analysis showed YKL-40 to correlate positively with age, AST, ALP and γ-GTP, but inversely with ABI (Table 4). There was a tendency toward inverse relationships between YKL-40 and MAC, TSF and GNRI, three measures that are generally found to be low in a malnourished state, although these relationships were not significant (Table 4). Prior to the multiple regression analysis, independent variables were selected by eliminating multicollinearity with a variance inflation factor over 10 (data not shown). Age, γ-GTP and GNRI were found to be independently associated with YKL-40, allowing selection of a higher coefficient of determination for the adjusted r-square (R²) (Table 5).

DISCUSSION

A prior study detected no correlation between the serum concentration of YKL-40 and creatinine in healthy subjects (42). A hemodynamic evaluation, however, revealed decreased plasma YKL-40 concentrations in the renal vein (43). Dialysis reportedly reduced serum YKL-40 concentrations by approximately one-sixth (44). We can reasonably speculate that renal clearance of YKL-40 was reduced, resulting in systemic accumulation which in turn resulted in a YKL-40 value three times that in

education by a dietitian.

Written informed consent was obtained from all subjects. The study protocol was approved by the institutional review board of Eijin Clinic (No.2018-01) and Kamakura Women’s University (No.19014-1). The study was registered with the University Hospital Medical Information Network (UMIN) clinical trial registry (UMIN ID : UMIN000040897) and fully adhered to the guidelines of the Declaration of Helsinki.

Laboratory procedures

Blood samples were collected before the first dialysis session of the week. Serum albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT), γ-glutamyl transpeptidase (γ-GTP), urea nitrogen, uric acid, creatinine, total cholesterol, triacylglycerol levels, total ion binding capacity (TIBC), hematocrit, and lymphocyte count were determined employing standard laboratory techniques with the use of an automatic analyzer. Serum prealbumin and high-sensitivity C-reactive protein (hs-CRP) were quantified by laser nephelometry. YKL-40 and interleukin-6 (IL-6) were quantified by a double-sided sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems; Minneapolis, MN, USA). We referred to the following reference value for healthy subjects: a serum YKL-40 level of 46.1 ± 19.4 ng/mL, an hs-CRP level of 0.08-0.17 mg/mL and an IL-6 level of 1.3-2.0 pg/mL (30-34). The HD dose was calculated using the following equation:

$$Kt/V = \frac{1}{\ln(R - 0.008 \times t + 4 - (3.5 \times R) \times UF/W)}$$

where $Kt/V$ is single-pool $Kt/V$, $R$ is the ratio of post-dialysis to pre-dialysis serum urea nitrogen, $t$ (in hours) is the duration of dialysis, UF is the ultrafiltrate volume (L) and $W$ (kg) is the post-dialysis body weight (35).

Evaluation of protein intake

Dietary protein intake was measured to determine the normalized protein catabolic rate (nPCR), which was calculated using the equation published by the Kidney Disease Outcomes Quality Initiative (K/DOQI) Hemodialysis Adequacy Working Group:

$$nPCR = \frac{C_{\text{U}} \times 36.3 + 5.48 \times (Kt/V) \times 53.5 + 0.168}{W}$$

where $C_{\text{U}}$ (mg/dL) is the pre-dialysis concentration of serum urea nitrogen. The data collected during the first dialysis session of the week were used for these calculations (35).

Anthropometric measurements

Patients were weighed before and after each dialysis session and the post-dialysis body weight served as the dry weight. The body mass index (BMI) was calculated from the dry weight. Mildarm circumference (MAC) was measured using an Inser-Tape (Abbott Japan Co., Ltd., Tokyo, Japan) and triceps skinfold thickness (TSF) was measured using MK-60 skinfold calipers (Yagami Co., Ltd., Aichi, Japan) on the limb not being used for vascular access. The mid-upper arm muscular area (MAMA) was calculated using the following equation:

$$MAMA = (MAC - 31.4 \times TSF)^2 / 12.56$$

MAMA, MAC, and TSF were measured in cm.

The ankle brachial index (ABI) score, an index used to evaluate peripheral arterial disease, was measured using a BP-203RPEII network arteriosclerosis detection device (Omron Healthcare, Kyoto, Japan).

Geriatric Nutritional Risk Index

The Geriatric Nutritional Risk Index (GNRI), a nutritional assessment tool for HD patients, was calculated from serum albumin concentrations and body weight using the following equation:

$$\text{GNRI} = \frac{[14.89 \times \text{serum albumin (g/dL)}] + [41.7 \times \text{body weight (kg)}]}{\text{ideal body weight (kg)}}$$

Body weight / ideal body weight was set to 1 when the subject’s body weight exceeded the ideal body weight. Ideal body weight in this study was defined as the value calculated from the subject’s height and a body mass index (BMI) of 22 (kg/m²). Malnutrition risk was defined as a GNRI under 91.2 (36). GNRI reportedly predicts mortality in HD patients (37-39). It is thus widely used in clinical settings at present (40).

Statistical analysis

All variables are presented as the mean ± SD. Univariate analysis was performed to examine the relationships between YKL-40 and other parameters employing Spearman’s rank correlation coefficient. Multivariate analysis was performed for parameters showing significant differences. Potential confounding factors for increased YKL-40 were assessed using a multiple regression analysis model based on general variables, atherosclerosis markers and correlations with PEW (p<0.10). Two-sided P values of <0.05 were considered to be statistically significant in all analyses. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (41).
### Table 1. Characteristics of patients on HD

|                         | All patients (n = 88) | Male (n = 65) | Female (n = 23) | p     |
|-------------------------|-----------------------|---------------|-----------------|-------|
| Age (y)                 | 68.5 ± 13.5           | 68.5 ± 12.5   | 68.6 ± 15.9     | NS    |
| Duration of dialysis (y)| 6.2 ± 5.8             | 6.3 ± 6.0     | 5.9 ± 5.1       | NS    |
| Diabetes (%)            | 52.3                  | 55.4          | 43.5            | NS    |
| Smoking (%)             | 69.5                  | 83.3          | 33.3            | 3.420E-5 |
| BMI (kg/m²)             | 22.5 ± 3.8            | 22.8 ± 3.6    | 21.5 ± 4.3      | NS    |
| MAC (cm)                | 24.6 ± 3.0            | 25.0 ± 3.0    | 23.3 ± 2.5      | 0.020 |
| TSF (mm)                | 10.6 ± 5.4            | 10.3 ± 5.3    | 11.5 ± 5.5      | NS    |
| MAMC (cm)               | 21.2 ± 2.9            | 21.7 ± 2.9    | 19.7 ± 2.1      | 0.002 |
| ABI                     | 1.16 ± 0.14           | 1.17 ± 0.15   | 1.13 ± 0.12     | NS    |
| GNRI                    | 91.4 ± 5.1            | 92.0 ± 5.0    | 89.9 ± 4.8      | NS    |
| Prevalence of malnutrition by GNRI | 45.4                | 41.3          | 56.5            | NS    |
| nPCR (g/kg/day)         | 0.83 ± 0.16           | 0.83 ± 0.16   | 0.86 ± 0.18     | NS    |

1Mann-Whitney U test

### Table 2. Blood analysis of HD patients

| Marker                  | All patients (n = 88) |
|-------------------------|-----------------------|
| Albumin (g/dL)          | 3.49 ± 0.24           |
| Prealbumin (mg/dL)      | 27.0 ± 6.2            |
| ALP (IU/L)              | 219.1 ± 88.6          |
| AST (IU/L)              | 10.9 ± 6.9            |
| ALT (IU/L)              | 11.0 ± 8.0            |
| γ-GTP (IU/L)            | 24.3 ± 17.5           |
| Urea nitrogen (mg/dL)   | 58.8 ± 13.6           |
| Uric acid (mg/dL)       | 7.5 ± 1.6             |
| Creatinine (mg/dL)      | 10.0 ± 2.6            |
| Total cholesterol (mg/dL)| 147.9 ± 28.9          |
| Triacylglycerol (mg/dL) | 107.3 ± 67.2          |
| TIBC (mg/dL)            | 230.8 ± 54.2          |
| hs-CRP (mg/dL)          | 0.24 ± 0.51           |
| YKL-40 (mg/mL)          | 157.9 ± 85.5          |
| IL-6 (pg/mL)            | 26.1 ± 17.6           |
| Hematocrit (%)          | 31.1 ± 3.3            |

### Table 3. Primary diseases leading to HD

| Disease                                          | Number of patients |
|--------------------------------------------------|--------------------|
| Diabetic nephropathy (excluding cases of diabetes diagnosed after HD therapy) | 44                 |
| Chronic glomerulonephritis                       | 18                 |
| Renal sclerosis                                  | 16                 |
| Polycystic kidney disease                        | 1                  |
| Cause unknown                                    | 4                  |
| Others                                           | 5                  |

### Table 4. Correlation of YKL-40 with hematological, inflammatory, nutritional and anthropometric markers

| Marker                  | YKL-40 | r     |
|-------------------------|--------|-------|
| Age (y)                 | 2.820E-5 | 0.431 |
| Duration of dialysis (y)| NS     | 0.061 |
| BMI (kg/m²)             | NS     | -0.163|
| MAC (cm)                | 0.080  | -0.198|
| TSF (mm)                | 0.056  | -0.216|
| MAMC (cm)               | NS     | -0.040|
| ABI                     | 1.740E-3 | -0.345|
| GNRI                    | 0.073  | -0.194|
| nPCR (g/kg/day)         | NS     | -0.120|
| Albumin (g/dL)          | NS     | -0.092|
| Prealbumin (mg/dL)      | NS     | -0.152|
| ALP (IU/L)              | 0.045  | 0.214 |
| AST (IU/L)              | 0.014  | 0.262 |
| ALT (IU/L)              | NS     | -0.078|
| γ-GTP (IU/L)            | 0.021  | 0.246 |
| Blood urea nitrogen (mg/dL)| NS    | -0.131|
| Urea acid (mg/dL)       | 0.081  | -0.187|
| Creatinine (mg/dL)      | NS     | -0.131|
| Total cholesterol (mg/dL)| NS    | 0.013 |
| Triacylglycerol (mg/dL) | NS     | -0.050|
| TIBC (mg/dL)            | NS     | -0.012|
| hs-CRP (mg/dL)          | NS     | 0.114 |
| IL-6 (pg/mL)            | NS     | -0.069|
| Hematocrit (%)          | NS     | 0.080 |

Spearman’s rank correlation coefficients were used
Table 5. Association between parameters and YKL-40 by multiple regression analysis

| Variables | β    | SE  | p     |
|-----------|------|-----|-------|
| Intercept | 517.444 | 177.124 | 0.005 |
| age       | 1.577 | 0.625 | 0.014 |
| γ-GTP     | 1.962 | 0.480 | 0.006 |
| GNRI      | -4.291 | 1.630 | 0.010 |
| ABI       | -103.160 | 58.916 | 0.084 |
| Gender (male) | 15.580 | 18.568 | 0.404 |

β, partial regression coefficient; SE, standard error. Adjusted R2, 0.300; p=7.55E-6

healthy subjects.

YKL-40 levels of HD patients have been reported to be related to nutritional parameters, such as serum albumin, hemoglobin and BMI (26, 27). In this study, YKL-40 levels were not significantly associated with these traditional nutritional parameters. This difference may be due to the fact that, unlike previous reports, about half of patients in this study were undernourished by GNRI. Thus, the values for the anthropometric indices MAC and TSF (p = 0.056) and the nutritional assessment measure GNRI (p = 0.073) tended to be inversely related to YKL-40. In the multiple regression analysis, GNRI was only independently associated with YKL-40 (Table 5). However, in line with previous reports, YKL-40 was related to nutritional status. In order to clarify the association between YKL-40 and anthropometric indices as markers of nutritional status in HD patients, a cross-sectional study is needed, rather than the longitudinal design of the present study.

Previous studies found YKL-40 to be either moderately or only slightly associated with inflammatory parameters (26, 27, 45, 46). In the present study, YKL-40 showed no significant association with either hs-CRP or IL-6, apparently reflecting differences in the expression or the turn-over of these factors in HD patients. The opposite tendency was observed, i.e., there was no significant difference between the YKL-40 levels in diabetic patients as compared with non-diabetic subjects, despite diabetes being related to atherosclerosis, inflammation and chronic renal failure (22). Furthermore, YKL-40 became increasingly elevated with progression of diabetic nephropathy (23-25). To our knowledge, no studies have measured YKL-40 levels in diabetic HD patients. In HD patients, another factor beyond the pathogenic factors associated with diabetes might be the influence of YKL-40 elevation itself. Previous studies have reported high YKL-40 protein expression within activated macrophages and atherosclerotic lesions, in contrast to the systemic reactions involved in hepatic synthesis of inflammatory mediators (4, 5). Previous reports have also noted that YKL-40 levels in patients on HD fluctuated from normal to high-range values. Thus, YKL-40 elevation in patients receiving HD, as demonstrated in prior studies might have contributed to the development of hepatic disorders. In the univariate analysis, YKL-40 correlated with ALP, AST and γ-GTP. However, our study criteria specifically excluded patients with hepatic disorders, including fatty liver detected by CT, such that we cannot conclude that the observed correlation is attributable to hepatic dysfunction. Further study is required, with detailed examination and following up of the HD patients with mild forms of liver damage such as fatty liver.

In relation to chronic inflammation, previous studies have suggested that an increase in YKL-40 serum level with HD may indicate unresolved low-grade inflammation and abnormal local tissue remodeling such as within the vessel wall (47-49). In the present study, the atherosclerosis marker ABI was significantly associated with YKL-40. However, ABI was not independently associated with YKL-40 in the multiple regression analysis. A previous study reported that γ-GTP showed a significant positive association with atherosclerosis in elderly Japanese men (50). In the present study, age and γ-GTP were independently associated with YKL-40 in HD patients. A rise in YKL-40 level with age has been described in the general population, but this is reportedly controversial in HD patients (26, 27, 30, 51). Aging was suggested to increase chronic inflammation in blood vessels (51). Blood vessel inflammation was also reported to be associated with YKL-40 levels (3-5). The precise mechanism(s) underlying the association of YKL-40 with age in the general population and, particularly, in HD patients awaits investigation of age- and inflammation-related cytokines, though it is noteworthy that CRP and IL-6 were not related to YKL-40 in our present study. γ-GTP has been reported to be associated with inflammation in patients with metabolic diseases and hepatitis C virus infections (52-54). Inflammation associated with metabolic disease may be affecting YKL-40 level. Patients in this study had a high prevalence of diabetes; however, this prevalence was not significantly related to other factors (data not shown).

This study has limitations. First, the sample size was small. However, the size was adequate as the correlation coefficient of r = 0.431 on the univariate analysis of YKL-40 with age, an association which has already been convincingly demonstrated, requires no more than 50 samples (26, 51). Second, this study was a cross-sectional analysis. Not only the malnutrition status of HD patients, but also the chronic worsening of inflammation and atherosclerosis were taken into account. It is necessary to consider the relationships between YKL-40 and parameters of atherosclerosis, including PWV, CAVI, and central blood pressure, in HD patients. A prospective study is required to examine the association of YKL-40 with additional parameters. Furthermore, longitudinal study to examine the relationships of YKL-40 with GNRI, another nutritional parameter, and nutritional disorders would allow for the assessment of a possible correlation with mortality.

In conclusion, this study found that YKL-40 elevation was associated with age, GNRI and γ-GTP in patients on HD. This suggests that YKL-40 may contribute to malnutrition and metabolic disorders such as age-related chronic inflammatory diseases, in HD patients. Further study is needed to elucidate the possible relationships of YKL-40 with other factors in the HD setting.

CONFLICT OF INTEREST

The authors have no conflicts of interest related to the content of this article.

ACKNOWLEDGEMENTS

We are indebted to Marin Okuda, Mizuho Otobe, Yui Fukumoto and Noriko Mikami for assistance in conducting this study, and we thank Philip Hawke of the University of Shizuoka Scientific English Program for his comments on the English in the manuscript. We certify that all persons named, with their specific contributions in the acknowledgement section, made substantial contributions to the work but did not fulfill the authorship criteria.
REFERENCES

1. Johansen JS, Jensen BV, Roslund A, Nielsen D, Price PA: Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15: 194-202, 2006

2. Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE: Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 137: 2696-704, 2015

3. Nishikawa KC, Millis AJ: gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 287: 79-87, 2003

4. Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krogh-Sorensen K, Klingvall MF, Brosstad F, Oie E, Vestergaard H, Aukrust P: Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis 211: 589-95, 2010

5. Rathcke CN, Vestergaard H: YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55: 221-7, 2006

6. Mushtaq S, Ghani E, Azam K, Hussain T: Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography. Eur J Gastroenterol Hepatol 31: 357-362, 2019

7. Yan L, Deng Y, Zhou J, Zhao H, Wang G, Group CHRFAR: Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection 46: 385-393, 2018

8. Tatár B, Kose S, Pala E, Tatár B: Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients. Acta Medica (Hradec Kralove) 60: 71-75, 2017

9. Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Matsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhattacharya S, Shlipak MG, Ljunggren PO: Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 6: 53528, 2016

10. Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitering F, Roeb E, Zachoval R: YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 46: 1369-80, 2011

11. Fontana RD, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL, HALT-C Trial Group: Serum fibrosis markers are associated with disease progression in non-responder patients with chronic hepatitis C. Gut 59: 1401-9, 2010

12. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Noonan A, Massoud M, Koziel MJ, Afdaal NH: Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43: 771-9, 2006

13. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bentdensen F: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32: 911-20, 2000

14. Tao H, Yang JJ, Shi KH, Huang C, Zhang L, Lv XW, Li J: The significance of YKL-40 protein in liver fibrosis. Inflamm Res 63: 249-54, 2014

15. Paschetta E, Beli P, Alisi A, Licardio D, Cutrera R, Musso G, Nobili V: OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm 815721, 2015

16. Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS: YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and mendelian randomization studies. Clin Chem 60: 1429-40, 2014

17. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kogple JD: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 42: 864-81, 2003

18. Albeltagy ES, Abdul-Mohyamen AM, Taha DR: Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU: a pilot study. Int Urol Nephrol 52: 351-361, 2020

19. Bullen AL, Katz R, Lee AK, Anderson AM, Cheung AK, Garimella PS, Jotwani V, Haley WE, Ishani A, Lash JP, Neyra JA, Punzi H, Rastogi A, Riessen E, Malhotra R, Parikh CR, Rocco MV, Wall BM, Bhattacharya S, Shlipak MG, Ljunggren PO: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 62: 1401-9, 2010

20. Huen SC, Parikh CR: Molecular phenotyping of clinical AKI with novel urinary biomarkers. Am J Physiol Renal Physiol 309: F406-13, 2015

21. Hall IE, Stern EP, Cantley LG, Elias JA, Parikh CR: Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients. BMC Nephrol 15: 133, 2014

22. Kapoula GV, Kontou PI, Bagos PG: Diagnostic Performance of Biomarkers Urinary KIM-1 and YKL-40 for Early Diabetic Nephropathy, in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diagnostics (Basel)10, 2020

23. Schrauben SJ, Shou H, Zhang X, Anderson AH, Bonventre JV, Chen J, Coca S, Furth SL, Greenberg JH, Gutierrez OM, IX JH, Lash JP, Parikh CR, Rebolho CM, Sabhiatti V, Sarnak MJ, Shlipak MG, Wiark SS, Kimmeli PL, Vasan RS, Feldman HI, Schelling JR, CKD Biomarkers Consortium and the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 32:115-126, 2021

24. Nadkarni GN, Chauhan K, Rao V, IX JH, Shlipak MG, Parikh CR, Coca SG: Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants. Am J Kidney Dis 73: 31-38, 2019

25. Zarawska-Plaskoj E, Ługowska A, Hetmańczyk K, Knapik Kordecka M, Adamiec R, Piwowar A: Proteins from the 18 glycosyl hydrolase family are associated with kidney dysfunction in patients with diabetes type 2. Biomarkers 20: 52-7, 2015

26. Oktay GU, Er RE, Tekbudak MY, Paşaçoğlu Ö, Inal S, Öneç K, Paşaçoğlu H, Altok K, Doriçi Ü, Erten Y: Novel inflammatory marker in dialysis patients: YKL-40. Ther Apher Dial 17: 193-201, 2013

27. Lorenz G, Schmalenberg M, Kemmner S, Haller B, Steubl O, Küchle C, Thürmel K, Renders L, Bauer A, Baumann M, Heemann U, Lupa PB, Schmaderer C: Mortality prediction in stable hemodialysis patients is refined by...
YKL-40, a 40-kDa glycoprotein associated with inflammation. Kidney Int 93: 221-230, 2018
28. Persson F, Borg R: YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology. Kidney Int 85: 21-22, 2019
29. Vega A, Sánchez-Niño MD, Ortiz A, Abad S, Macías N, Aragóncillo I, Santos A, García-Prieto A, Torres E, Hernández A, Sánchez-Cámara L, Hurtado E, Valiño-Rivas L, Luño J: The new marker YKL-40, a molecule related to inflammation, is associated with cardiovascular events in stable haemodialysis patients. Clin Kidney J 13: 172-178, 2020
30. Waszczykowski M, Fabiš-Strobin A, Bednarski I, Lesiak A, Narbutt J, Fabiš J: Serum Biomarkers of Inflammation and Turnover of Joint Cartilage Can Help Differentiate Psoriatic Arthritis (PsA) Patients from Osteoarthritis (OA) Patients. Diagnostics (Basel) 11: 52, 2020
31. Shine B, de Beer FC, Pepys MB: Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta 117: 13-23, 1981
32. Garvin F, Nilsson E, Ernerudh J, Kristensson M: The joint subclinical elevation of CRP and IL-6 is associated with lower health-related quality of life in comparison with no elevation or elevation of only one of the biomarkers. Qual Life Res. 25: 213-21, 2016
33. Tsai DH, Amyai N, Marques-Vidal P, Wang JL, Riediker M, Persson F, Borg R: YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology. Kidney Int 93: 21-22, 1997
34. Nielsen TL, Plesner LL, Warming PE, Palmiggaard JL, Dalsgaard M, Schou M, Høst U, Rydahl C, Brandt L, Kober L, Johansen JS, Krastrup J, Iversen KK: YKL-40 in patients with end-stage renal disease receiving haemodialysis. Biomarkers 23: 357-363, 2018
35. Johansen JS, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK, Bruunsgaard H: High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 151: 260-6, 2008
36. Pawlak K, Rozkwiecz D, Mysiwiec M, Pawlak D: YKL-40 in hemodialyzed patients with and without cardiovascular complications - the enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine 82: 75-80, 2013
37. James AJ, Reinius LE, Verhoeck M, Gomes A, Kupczyk M, Hammar U, Ono J, Ohta S, Izuhara K, Bel E, Kere J, Söderhäll C, Dahlén B, Boot RG, Dahlén SE, BIAOAR (Lougitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease): Consortium Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 193: 131-42, 2016
38. Létuve S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kienzer PA, Aubier M, Coyle AJ, Pretolani M: YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 181: 5167-73, 2008
39. Lee CG, Hartl D, Lee GR, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homor RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA: Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 206: 1149-66, 2009
40. Shimizu Y, Kawashiri SY, Kiyoura K, Nobuske K, Yamanashi N, Nagata Y, Maeda T: Gamma-glutamyl transpeptidase (γ-GTP) has an ambivalent association with hypertension and atherosclerosis among elderly Japanese men: a cross-sectional study. Environ Health Prev Med 24: 69, 2019
41. Bojesen SE, Johansen JS, Nordestgaard BG: Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 412: 709-12, 2011
42. Yamazaki J, Ichikawa Y, Goda T: Circulating interleukin-1β concentrations are independently-positively associated with γ-glutamyltransferase activity within the normal range in middle-aged apparently healthy Japanese women. J Nutr Sci Vitaminol (Tokyo) 59: 526-32, 2013
43. Mochizuki K, Misaki Y, Miyasaka R, Akabe S, Shimada M, Ichikawa Y, Goda T; Associations between markers of liver injury and cytokine markers for insulin sensitivity and inflammation in middle-aged Japanese men not being treated for metabolic diseases. J Nutr Sci Vitaminol (Tokyo) 57: 409-17, 2011
44. Abe H, Ochi H, Maekawa T, Hayes CN, Tauge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Ohishi W, Arhiro K, Kubo M, Nakamura Y, Chayama K: Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439-43, 2010